Phenylethyl resorcinol-containing composition as well as preparation method and application thereof

Abstract

The invention relates to the technical field of cosmetics and external preparations, in particular to a phenethyl resorcinol-containing composition as well as a preparation method and application thereof. The composition containing phenylethyl resorcinol is prepared from the following raw materials in parts by mass: 0.5 to 3 parts of recombinant collagen, 0.1 to 1 part of sodium hyaluronate, 0.1 to 1 part of phenylethyl resorcinol, 0.01 to 0.1 part of glabridin, 0.2 to 1 part of beta-glucan wrapped by lipidosome, 1 to 3 parts of composite antioxidant, 0.1 to 1 part of chitosan, 0.5 to 2 parts of emulsifier, 3 to 8 parts of humectant and the balance of water, totaling 100 parts by mass. The composite antioxidant contains 40 wt% or more of shea butter modified by polyhydric alcohol, and the number-average molecular weight of the polyhydric alcohol is 50-200. Through the synergistic effect of beta-glucan and PEG modified shea butter, the transdermal absorption effect of the composition is remarkably enhanced, the blackening phenomenon of the skin is effectively improved, and the moisture content of the skin is increased.

Description

Technical Field

[0001] This invention relates to the field of cosmetics and topical preparations, specifically to a phenylethyl resorcinol-containing composition, its preparation method, and its application. Background Technology

[0002] In the field of cosmetics and topical skin repair, skin care for wounds (such as superficial wounds, small abrasions, abrasions, cuts, laser treatments, photofacials, chemical peels, hydrogel treatments, post-micro-plastic surgery procedures, acne, and other non-chronic wounds) not only needs to promote wound healing, but also needs to address pigmentation issues such as hyperpigmentation that may occur around the wound.

[0003] In existing technologies, although the combination of phenylethyl resorcinol and glycyrrhizin can inhibit melanin production, both have large molecular weights (phenylethyl resorcinol M...). w =268.32, glycyrrhizin M w =366.39), highly lipid-soluble, and with insufficient transdermal efficiency (in vitro permeation <3μg / cm). 2 The high concentrations of resorcinol (·h) in traditional compositions result in slow clinical onset, requiring high concentrations and potentially irritating the skin. Furthermore, these compositions lack the synergistic effect of repairing post-cosmetic hyperpigmentation and rebuilding the skin barrier function, and the highly active ingredients are easily oxidized and deactivated. Additionally, resorcinol derivatives are unstable, easily changing from milky white to pink or even brown. This limits their use in cosmetics or skin repair. Research has shown that the discoloration mechanism of resorcinol compounds is complex, involving oxidation, photosensitivity, and impurities. Developing highly stable resorcinol derivative compositions is of significant importance and holds promising industrial application prospects.

[0004] CN120381415A discloses a highly stable anhydrous self-assembled composition of resorcinol, comprising, by mass percentage: 20%–45% emulsifier; 10%–20% resorcinol derivative; 30%–60% polyol; 0.01%–0.1% pH adjuster; 0.01%–0.1% chelating agent; and 0.01%–0.1% antioxidant. The mass ratio of the emulsifier to the resorcinol derivative is 2–3:1. The emulsifier is composed of PPG-6-decyltetradecyl alcohol polyether-30 and PPG-4-cetyl alcohol polyether-20, wherein the mass percentage of PPG-6-decyltetradecyl alcohol polyether-30 in the emulsifier is greater than 50%. This patent employs a special combination of emulsifiers and polyols to form a self-assembled O / P vesicle system with resorcinol derivatives. This system effectively protects the resorcinol derivatives, isolating them from reactive oxygen species and delaying the oxidation of phenolic hydroxyl compounds. The stability of the active ingredient can reach over 90% after one month at high temperature (50°C). The combined use of PPG-4-cetyl alcohol polyether-20 and PPG-6-decyltetradecyl alcohol polyether-30, through the combination of low-carbon chain polyols and suitable PPG-type polyether emulsifiers, allows the hydroxyl groups of the polyols to form hydrogen bonds with the emulsifiers, enhancing the strength and tightness of the interfacial film and forming a stable balanced system. This effectively isolates the active ingredient from the external environment, thereby improving the stability of the active ingredient and reducing skin irritation.

[0005] CN120661402A discloses a nanoemulsion composition comprising a nanoemulsion and nucleic acids loaded on the surface of the nanoemulsion. The nanoemulsion contains an active ingredient, an emulsifier, a skin moisturizer, an antioxidant, a humectant, and water. The active ingredient includes barrier-repairing lipids, which include sphingolipids, specifically phytosphingosine. The barrier-repairing lipids also include one or more of ceramides, free fatty acids, and cholesterol. The nucleic acid constitutes 0.1%-0.6% of the total mass of the nanoemulsion composition. The active ingredient also includes glycyrrhizin, salicylic acid, astaxanthin, and phenylethyl resorcinol. The skin moisturizer includes one or more of polymers, plant oils, animal oils, mineral oils, and synthetic oils, including shea butter. The active ingredient includes saccharide derivatives, specifically β-glucan.

[0006] However, a common drawback of existing skin-whitening and freckle-removing compositions containing phenylethyl resorcinol, or compositions used for skin repair, is their generally poor transdermal absorption. This is because the active ingredients, phenylethyl resorcinol and glycyrrhizin, have relatively large molecular weights: phenylethyl resorcinol has a molecular weight of 268.3, and glycyrrhizin has a molecular weight of 366.4. The ideal molecular weight for transdermal absorption is generally considered to be less than 500 Da. Although these two ingredients are still within the permeable range, they are approaching the upper limit. The larger the molecular weight, the slower the diffusion rate, and the more difficult it is to penetrate the micro-gaps between the scaly structures of the stratum corneum. This directly leads to low in vitro penetration. In addition, phenylethyl resorcinol and glycyrrhizin are typical lipid-soluble ingredients, which are more easily dissolved in oily media. The stratum corneum of the skin has a lipid bilayer. Although lipid-soluble ingredients are easily distributed into these lipid regions, to completely penetrate the entire stratum corneum and reach the active epidermal layer and even the dermis, a certain degree of water solubility (hydrophilicity) is required for distribution and diffusion in the aqueous environment such as intercellular lipids and keratinocytes. Excessive lipid solubility and extremely poor water solubility can cause the ingredients to remain in the lipids of the stratum corneum, making it difficult to continue to be effectively delivered to deeper layers, resulting in low bioavailability. Summary of the Invention

[0007] To address the shortcomings of existing skin-containing compositions using phenylethyl resorcinol, which lack sufficient stability and skin permeability, this invention proposes a multi-target synergistic repair composition containing phenylethyl resorcinol. Through the synergistic effect of β-glucan and PEG-modified shea butter, the transdermal absorption of the composition is significantly enhanced. This is of great significance for the development of pharmaceutical compositions using phenylethyl resorcinol and its derivatives as active ingredients in skin repair, whitening, and pigmentation removal. Specifically, this invention provides the following technical solutions to address the aforementioned technical problems:

[0008] A composition containing phenylethyl resorcinol, comprising the following raw materials in parts by weight: 0.5-3 parts recombinant collagen, 0.1-1 parts sodium hyaluronate, 0.1-1 parts phenylethyl resorcinol, 0.01-0.1 parts glycyrrhizin, 0.2-1 parts liposome-encapsulated β-glucan, 1-3 parts composite antioxidant, 0.1-1 parts chitosan, 0.5-2 parts emulsifier, 3-8 parts humectant, and water to a total of 100 parts by weight; wherein the composite antioxidant contains more than 40 wt% of polyol-modified shea butter resin, and the number average molecular weight of the polyol is 50-200.

[0009] Further, the multi-target synergistic repair composition containing phenylethyl resorcinol comprises the following raw materials in parts by weight: 0.5-2 parts recombinant collagen, 0.3-0.8 parts sodium hyaluronate, 0.2-0.5 parts phenylethyl resorcinol, 0.01-0.05 parts glycyrrhizin, 0.3-0.8 parts liposome-encapsulated β-glucan, 1-2.5 parts composite antioxidant, 0.1-0.3 parts chitosan, 1-1.5 parts emulsifier, and 3-5 parts moisturizer; wherein the composite antioxidant contains more than 50 wt% of polyol-modified shea butter resin, and the number average molecular weight of the polyol is 50-75.

[0010] Furthermore, the recombinant collagen is recombinant type III humanized collagen; the chitosan has a molecular weight of 10,000-50,000 Daltons and a degree of deacetylation of 80-90%; and the sodium hyaluronate has a molecular weight of 100kDa-200kDa.

[0011] Furthermore, the polyol is at least one of polyethylene glycol and polypropylene glycol.

[0012] Furthermore, the β-glucan particles encapsulated by liposomes have a particle size of 50-200 nm and an encapsulation efficiency of ≥85%.

[0013] Furthermore, methods for preparing liposome-encapsulated β-glucan are well known in the art. For example, in one embodiment, it is prepared according to a method including the following steps:

[0014] (1) Soybean lecithin and cholesterol are dissolved in an organic solvent and evaporated under reduced pressure in a water bath until the organic solvent is completely evaporated, forming a uniform lipid film on the inner wall of the reaction vessel.

[0015] (2) Add a buffer solution of β-glucan to a container in which a uniform lipid film is formed on the inner wall, and stir or shake in a water bath to fully hydrate the lipid film and spontaneously form a liposome suspension encapsulating β-glucan.

[0016] (3) The liposome suspension was processed by a high-pressure microfluidic homogenizer or an ultrasonic cell disruptor, and the conditions were controlled to make the liposome particle size distribution in the range of 50-200 nm.

[0017] Furthermore, in step (1), the mass ratio of soybean lecithin to cholesterol is 4-8:1, for example, 5-6:1; the water bath temperature is 40-60℃; in step (2), the organic solvent is selected from at least one of ethanol, chloroform, and ethyl acetate; the concentration of the β-glucan buffer solution is 1-20 mg / mL, preferably 3-10 mg / mL, for example, 5-7 mg / mL; the solvent is PBS buffer solution with pH=7.2-7.4; the amount of β-glucan buffer solution used is such that the mass ratio of soybean lecithin in step (1) to β-glucan in step (2) is 15-25:1, for example, 20:1; the stirring or shaking time is 1-5 h, for example, 1-2 h.

[0018] Further, the composite antioxidant includes at least one of polyol-modified shea butter, phycocyanin, glutathione mimic peptide, tocopheryl acetate, and ergothioneine, and the polyol-modified shea butter accounts for more than 40 wt%; preferably, the polyol-modified shea butter accounts for 40-70 wt%, such as 50-60 wt%. Further, the polyol-modified shea butter is PEG50-200 shea butter; preferably PEG50-100 shea butter, more preferably PEG50-75 shea butter.

[0019] Preferably, the composite antioxidant is a mixture of tocopherol acetate, ergothioneine, and polyol-modified shea butter in a mass ratio of 1-1.2:1-1.2:2-3.

[0020] The inventors discovered that liposome-encapsulated β-glucan and shea butter modified with a specific molecular weight polyol have a synergistic effect in improving the transdermal absorption of the composition. This synergistic effect requires both β-glucan encapsulation by liposomes and shea butter modified with a specific molecular weight polyol. The inventors analyzed that this is likely because β-glucan is a water-soluble macromolecule that has difficulty penetrating the intact stratum corneum. Liposome encapsulation converts it from hydrophilic to lipophilic, solving the problem of insufficient transdermal penetration. Liposomes can bind with free active ingredients in the composition through non-covalent bonds or form mixed micelles, achieving co-delivery of lipophilic active ingredients and β-glucan. Shea butter itself is an excellent emollient and film-forming agent. The inventors innovatively discovered that modification with a specific molecular weight polyol (such as PEG) in conjunction with liposome-encapsulated β-glucan can significantly improve the transdermal permeability of the composition. The inventors speculate that PEG-modified shea butter acts as a natural surfactant, and the oxygen atoms on the polyol chain can form hydrogen bonds with the polar heads of lipid molecules, increasing permeability. The molecular weight of the polyol needs to be strictly controlled. If the molecular weight is too small, the modified chain is too short, resulting in insufficient insertion and lipid layer perturbation capabilities; if the molecular weight is too large, the chain segments are too long, making it difficult to penetrate the stratum corneum and instead creating steric hindrance. Therefore, it is necessary to control the molecular weight of the polyol.

[0021] Furthermore, the emulsifier is selected from at least one of glyceryl stearate and cetearyl alcohol; and / or the humectant is selected from at least one of trehalose, glycerin, propylene glycol, and butylene glycol.

[0022] Furthermore, the phenylethyl resorcinol-containing composition further includes the following raw material in parts by weight: 0.1-0.2 parts tetrahydrocurcumin. The inventors also unexpectedly discovered that the introduction of tetrahydrocurcumin (THC) further enhances the transdermal absorption efficiency and anti-inflammatory repair function of the composition. As a highly stable reduced derivative of curcumin, tetrahydrocurcumin possesses excellent antioxidant, anti-inflammatory, and permeation-enhancing properties. Its small molecular weight (approximately 372 Da) and suitable lipid-water partition coefficient facilitate transdermal absorption. The inventors speculate that tetrahydrocurcumin may form multiple synergistic effects with liposome-encapsulated β-glucan, polyol-modified shea butter, and chitosan to further improve transdermal absorption efficiency and anti-inflammatory repair function:

[0023] 1. Synergistic effect with liposomes: Tetrahydrocurcumin can insert into the liposome bilayer membrane, enhance membrane fluidity, and promote the release and penetration of active ingredients;

[0024] 2. Synergistic effect with PEG-modified shea butter: The two can jointly form a mixed micelle structure, which can improve the solubility and transdermal efficiency of lipid-soluble active ingredients such as phenylethyl resorcinol.

[0025] 3. Synergistic effect with chitosan: Tetrahydrocurcumin carries a negative charge and can interact with positively charged chitosan through electrostatic interaction, prolonging its residence time on the skin surface and achieving a sustained-release effect;

[0026] 4. Synergistic effect with β-glucan: The anti-inflammatory effect of tetrahydrocurcumin and the immunomodulatory effect of β-glucan complement each other, jointly inhibiting postoperative inflammatory pigmentation.

[0027] The present invention also provides a method for preparing the above-mentioned phenylethyl resorcinol-containing composition, comprising the following steps:

[0028] (S1) Dissolve recombinant collagen and sodium hyaluronate in water and mix them evenly to obtain a mixed aqueous phase;

[0029] (S2) Phenethyl resorcinol, glycyrrhizin, a composite antioxidant, and an emulsifier are heated and mixed evenly to prepare an oil phase; preferably, tetrahydrocurcumin is also added.

[0030] (S3) β-glucan and chitosan encapsulated in liposomes are dispersed in a mixed aqueous phase and mixed evenly with a mixed oil phase under stirring. The mixture is then homogenized and emulsified. A humectant is added, the pH is adjusted to 6-7, the mixture is allowed to stand, and then filtered to obtain a composition containing phenylethyl resorcinol.

[0031] Furthermore, in step (S2), the heating temperature is 50-70℃, and in step (S3), the standing time is 24-48h, and the filtration is carried out using a 0.2-0.5μm sterile filter membrane, such as a 0.22μm sterile filter membrane.

[0032] The present invention also provides the use of the above-mentioned phenylethyl resorcinol-containing composition in the preparation of skin care products.

[0033] The phenylethyl resorcinol-containing composition provided by this invention contains a variety of components that work synergistically, especially β-glucan encapsulated by liposomes and shea butter modified with PEG of a certain molecular weight, which can improve the transdermal absorption of the composition, effectively improve skin hyperpigmentation, and increase skin moisture content. Detailed Implementation

[0034] The present invention will now be described in detail with reference to specific embodiments.

[0035] The recombinant collagen is recombinant type III humanized collagen, sourced from Bloomage Biotechnology (Tianjin) Co., Ltd.

[0036] Chitosan has a molecular weight of 20,000 Daltons and a degree of deacetylation of 80-90%; sodium hyaluronate has a molecular weight of 100-200 kDa.

[0037] Preparation Example

[0038] Ingredients: β-glucan (derived from oats, molecular weight approximately 100 kDa), soybean lecithin, cholesterol, phosphate buffer

[0039] Step 1, lipid film preparation: Soy lecithin and cholesterol are dissolved in ethanol at a mass ratio of 5:1, and then evaporated under reduced pressure in a 50°C water bath until the solvent is completely evaporated, forming a uniform lipid film on the inner wall of the container.

[0040] Step 2, hydration and encapsulation: Add PBS buffer solution (pH=7.2) containing 5 mg / mL β-glucan to the above container, and gently stir in a 50°C water bath for 2 hours to fully hydrate the lipid film and spontaneously form a liposome suspension encapsulating β-glucan;

[0041] Step 3, particle size homogenization: The liposome suspension is treated by a high-pressure microfluidic homogenizer, and the conditions are controlled to make the liposome particle size distribution in the range of 50-200 nm.

[0042] Step 4, Purification and Encapsulation Efficiency Determination: Unencapsulated free β-glucan is separated using ultrafiltration or gel chromatography, and the liposome fraction is collected. Encapsulation efficiency (EE) can be determined by a combination of centrifugation-supernatant method and phenol-sulfuric acid method, with an encapsulation efficiency controlled at 89.6%.

[0043] Example 1

[0044] (S1) Dissolve 0.5g of recombinant collagen and 0.3g of sodium hyaluronate in pure water and mix well to obtain a mixed aqueous phase;

[0045] (S2) Mix 0.2g phenylethyl resorcinol, 0.01g glycyrrhizin, 2g compound antioxidant (a mixture of tocopheryl acetate, ergothioneine and PEG-50 shea butter resin in a mass ratio of 1:1:2), and 1g emulsifier glyceryl stearate at 50°C to prepare an oil phase.

[0046] (S3) 0.3g of β-glucan encapsulated in liposomes prepared in the preparation example and 0.1g of chitosan were dispersed in the mixed aqueous phase and mixed evenly with the mixed oil phase under stirring. The mixture was homogenized and emulsified. 5g of humectant (a mixture of glycerol, propylene glycol and butylene glycol in a mass ratio of 10:1:1.5) was added, the pH was adjusted to 6.8, and pure water was added to make up to 100g. The mixture was allowed to stand for 24h and filtered through a 0.22μm sterile filter membrane to obtain a composition containing phenylethyl resorcinol.

[0047] Examples 2-4 and Comparative Examples 1-2 were prepared using the same method as in Example 1 above, with the difference being that the formulations are shown in Table 1 below:

[0048] Table 1. Composition Formulation

[0049]

[0050] Example 5

[0051] (S1) Dissolve 1.0g of recombinant collagen and 0.5g of sodium hyaluronate in pure water and mix well to obtain a mixed aqueous phase;

[0052] (S2) Mix 0.3g phenylethyl resorcinol, 0.03g glycyrrhizin, 2g compound antioxidant, 1g emulsifier glyceryl stearate, and 0.1g tetrahydrocurcumin at 50°C to prepare an oil phase.

[0053] (S3) 0.5g of β-glucan encapsulated in liposomes prepared in the preparation example, 0.1g of chitosan dispersed in the mixed aqueous phase, mixed evenly with the mixed oil phase under stirring, homogenized and emulsified, 5g of humectant added, pH adjusted to 6.8, pure water added to make up to 100g, allowed to stand for 24h, filtered through a 0.22μm sterile filter membrane to obtain a composition containing phenylethyl resorcinol.

[0054] Compared with Example 2, the formulation of Example 5 increased by 0.1g of tetrahydrocurcumin.

[0055] Example 6

[0056] The other operations and conditions are the same as in Example 5, except that in step S2, the amount of tetrahydrocurcumin added is 0.2g.

[0057] Example 7

[0058] The other components of the formulation are the same as those in Example 2 of Table 1, except that in the compound antioxidant, PEG-50 shea butter resin is replaced with an equal mass of PEG-75 shea butter resin.

[0059] Comparative Example 1

[0060] The other components of the formulation are the same as those in Example 2 in Table 1, except that in the composite antioxidant, PEG-50 shea butter is replaced with shea butter that is not modified by PEG.

[0061] Comparative Example 2

[0062] The other components of the formulation are the same as those in Example 2 in Table 1, except that the β-glucan encapsulated in the liposomes prepared in the preparation example is replaced with an equal mass of β-glucan.

[0063] Application Example 1

[0064] The compositions of the above examples and comparative examples were tested for their tyrosinase inhibition and transdermal absorption effects (Franz diffusion cell method, using phenylethyl resorcinol and glycyrrhizin as test components), and the results are shown in Table 2 below.

[0065] 1. Tyrosinase inhibition effect test

[0066] Reagents: L-tyrosine, mushroom tyrosinase, phosphate buffered saline (PBS, pH 6.8), and test samples (combinations used in examples and comparative studies).

[0067] Instruments: UV-Vis spectrophotometer (model: Shimadzu UV-1800), constant temperature water bath

[0068] Steps: 1. Dilute the sample to be tested with PBS to an effective concentration (equivalent to 0.1% phenylethyl resorcinol).

[0069] Add the following solutions sequentially to the 96-well plate: 50 μL PBS (blank group), 50 μL sample solution (experimental group), and 50 μL kojic acid solution (positive control group, 1 mg / mL).

[0070] Add 50 μL of tyrosinase solution (100 U / mL) to each well and incubate at 37°C for 10 minutes.

[0071] Add 50 μL of L-tyrosine substrate solution (2 mM) and react at 37°C for 30 minutes.

[0072] The absorbance (OD value) was measured at a wavelength of 475 nm.

[0073] calculate: ×100%

[0074] in:

[0075] OD sample: A sample group containing enzymes and substrates;

[0076] OD blank sample: Sample group without enzyme;

[0077] OD control: Enzyme reaction group without sample;

[0078] OD control blank: a blank group containing neither enzyme nor sample.

[0079] 2. Transdermal absorption effectThe experiment was conducted using the Franz vertical dual-chamber osmotic diffusion cell method, with phenylethyl resorcinol and glycyrrhizin as test components. Two-month-old piglet skin of the same size was fixed between the supply and receiving chambers of the Franz diffusion cell. The receiving chamber had a volume of 12 mL and used 20% ethanol-PBS buffer solution as the receiving solution. 0.1 g of the compositions from the examples and comparative examples was added to the supply chamber as the test sample. The diffusion cell was placed in a constant temperature water bath (32±1℃) with stirring at 300 rpm. Samples were taken at 2 h, 4 h, and 8 h, and the concentration of the test material in the receiving solution at different time points was determined using the HLPC-DAD method. The data were processed according to the following formula: Q=[Cn×V+∑Ci×V0] / S (i=1…n-1) to obtain the cumulative osmotic volume. Where Q: cumulative permeation volume; V: volume of receiving liquid in the receiving chamber; V0: volume of each sample taken; Ci: drug concentration in the receiving liquid from the first to the last sample taken; Cn: sample concentration measured at the nth sampling point.

[0080] Table 2 Composition Effect Tests

[0081]

[0082] Application Example 2

[0083] Recruiting Participants: Ten qualified participants are planned to be enrolled for the experiment using the composition of Example 5. Participants must meet the following criteria:

[0084] (1) Patients who have received light medical aesthetic treatments (such as laser freckle removal, photon skin rejuvenation, etc.) in the past 3-6 months and have experienced hyperpigmentation. (2) Age: 18-60 years old, male or female. (Except for pregnant or breastfeeding women) (3) Those who have not participated in other clinical trials on the test site in the past three months. (4) Those who do not have serious skin diseases (such as severe eczema, psoriasis, etc.), no history of skin allergies or allergies to any of the test components. (5) Those who are not highly sensitive. (6) Those who have not used hormone drugs or immunosuppressants in the past month. (7) Those who are willing to participate in the trial and sign the informed consent form. (8) Those who do not violate the exclusion criteria and can comply with the restrictions.

[0085] Instruments used: Minolta CM-700d skin color meter; Corneometer CM825 skin moisture meter; Tewameter TM300 transdermal water loss meter.

[0086] Experimental Methods: Volunteers used the composition of Example 5 for 28 consecutive days, comparing the left and right sides of their faces. Skin moisture was measured using a skin analyzer, skin moisture meter, and transepidermal water loss meter to obtain the final results. The left side used the composition of Comparative Example 1, and the right side used the composition of Example 5. Measurements were taken before product use (day 0, baseline), day 14, and day 28. ITA value and stratum corneum moisture content were calculated as follows: Improvement rate (%) = [(Day N value - Baseline value) / Baseline value] × 100%; TEWL value was calculated as [Improvement rate (%) = (Baseline value - Day N value) / Baseline value] × 100%. Results are shown in Table 3 below.

[0087] Table 3. Results of skin condition changes after sample use

[0088]

[0089] Based on the test results of indicators such as skin color improvement, skin moisture content, and transepidermal water loss rate, the formula in Example 5 showed the best effect in repairing hyperpigmentation after minimally invasive cosmetic procedures and in skin care. It can effectively improve hyperpigmentation, increase skin moisture content, and enhance skin barrier function, providing a strong basis for the optimization of repair products after minimally invasive cosmetic procedures.

Claims

1. A composition containing phenylethyl resorcinol, characterized in that, The raw materials include the following parts by weight: 0.5-3 parts recombinant collagen, 0.1-1 parts sodium hyaluronate, 0.1-1 parts phenylethyl resorcinol, 0.01-0.1 parts glycyrrhizin, 0.2-1 parts liposome-encapsulated β-glucan, 1-3 parts complex antioxidant, 0.1-1 parts chitosan, 0.5-2 parts emulsifier, 3-8 parts humectant, and water to a total of 100 parts by weight; wherein the complex antioxidant contains more than 40 wt% of polyol-modified shea butter resin, and the number average molecular weight of the polyol is 50-200.

2. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The multi-target synergistic repair composition containing phenylethyl resorcinol comprises the following raw materials in parts by weight: 0.5-2 parts recombinant collagen, 0.3-0.8 parts sodium hyaluronate, 0.2-0.5 parts phenylethyl resorcinol, 0.01-0.05 parts glycyrrhizin, 0.3-0.8 parts liposome-encapsulated β-glucan, 1-2.5 parts composite antioxidant, 0.1-0.3 parts chitosan, 1-1.5 parts emulsifier, and 3-5 parts moisturizer; wherein the composite antioxidant contains more than 50 wt% of polyol-modified shea butter resin, and the number average molecular weight of the polyol is 50-75.

3. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The recombinant collagen is recombinant type III humanized collagen; and / or chitosan has a molecular weight of 10,000-50,000 Daltons and a degree of deacetylation of 80-90%; and / or sodium hyaluronate has a molecular weight of 100kDa-200kDa; and / or the polyol is at least one of polyethylene glycol and polypropylene glycol; and / or the β-glucan encapsulated by liposomes has a particle size of 50-200nm and an encapsulation rate of ≥85%.

4. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The preparation method of liposome-encapsulated β-glucan includes the following steps: (1) Soybean lecithin and cholesterol are dissolved in an organic solvent and evaporated under reduced pressure in a water bath until the organic solvent is completely evaporated, forming a uniform lipid film on the inner wall of the reaction vessel. (2) Add a buffer solution of β-glucan to a container in which a uniform lipid film is formed on the inner wall, and stir or shake in a water bath to fully hydrate the lipid film and spontaneously form a liposome suspension encapsulating β-glucan. (3) The liposome suspension was processed by a high-pressure microfluidic homogenizer or an ultrasonic cell disruptor, and the conditions were controlled to make the liposome particle size distribution in the range of 50-200 nm.

5. The phenylethyl resorcinol-containing composition according to claim 4, characterized in that, In step (1), the mass ratio of soybean lecithin to cholesterol is 4-8:1, for example, 5-6:1; the water bath temperature is 40-60℃; in step (2), the organic solvent is selected from at least one of ethanol, chloroform, and ethyl acetate; the concentration of the β-glucan buffer solution is 1-20 mg / mL, preferably 3-10 mg / mL, for example, 5-7 mg / mL; the solvent is PBS buffer solution with pH=7.2-7.4; the amount of β-glucan buffer solution used is such that the mass ratio of soybean lecithin in step (1) to β-glucan in step (2) is 15-25:1, for example, 20:1; the stirring or shaking time is 1-5 h, for example, 1-2 h.

6. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The composite antioxidant includes at least one of polyol-modified shea butter, phycocyanin, glutathione mimic peptide, tocopheryl acetate, and ergothioneine, wherein the polyol-modified shea butter accounts for more than 40 wt%; preferably, the polyol-modified shea butter accounts for 40-70 wt%, such as 50-60 wt%; further, the polyol-modified shea butter is PEG50-200 shea butter; preferably PEG50-100 shea butter, more preferably PEG50-75 shea butter.

7. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The composite antioxidant is a mixture of tocopheryl acetate, ergothioneine, and polyol-modified shea butter in a mass ratio of 1-1.2:1-1.2:2-3; and / or the emulsifier is selected from at least one of glyceryl stearate and cetearyl alcohol; and / or the moisturizer is selected from at least one of trehalose, glycerin, propylene glycol, and butylene glycol.

8. The phenylethyl resorcinol-containing composition according to claim 1, characterized in that, The phenylethyl resorcinol-containing composition further includes the following raw materials in parts by weight: 0.1-0.2 parts of tetrahydrocurcumin.

9. A method for preparing a composition containing phenylethyl resorcinol, comprising the following steps: (S1) Dissolve recombinant collagen and sodium hyaluronate in water and mix them evenly to obtain a mixed aqueous phase; (S2) Phenethyl resorcinol, glycyrrhizin, a composite antioxidant, and an emulsifier are heated and mixed evenly to prepare an oil phase; preferably, tetrahydrocurcumin is also added. (S3) β-glucan and chitosan encapsulated in liposomes are dispersed in a mixed aqueous phase and mixed evenly with a mixed oil phase under stirring. The mixture is homogenized and emulsified, a humectant is added, the pH is adjusted to 6-7, the mixture is allowed to stand, and then filtered to obtain a composition containing phenylethyl resorcinol. Furthermore, in step (S2), the heating temperature is 50-70℃, and in step (S3), the standing time is 24-48h, and the filtration is carried out using a 0.2-0.5μm sterile filter membrane, such as a 0.22μm sterile filter membrane.

10. Use of the phenylethyl resorcinol composition according to any one of claims 1-9 in the preparation of skin care products.

Images